Live Breaking News & Updates on Elizabeth Swisher|Page 4
Stay updated with breaking news from Elizabeth swisher. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
IDEAYA Biosciences Appoints Dr. Frank McCormick as Chair of Scientific Advisory Board ycharts.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ycharts.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and. ....
PARP inhibitor is most effective in ovarian cancer patients with DNA repair mutations Appeared in BioNews 1094 New research suggests mutations in multiple DNA repair genes can determine how well ovarian cancer patients will respond to the PARP inhibitor, rucaparib. The authors of the study performed analyses on data from pre-treatment biopsies of tumours used in a phase 2 trial of rucaparib, to see if they could identify biomarkers that could predict a patient s response to treatment. PARP inhibitors are a drug class that has become an important therapeutic for ovarian and some other cancers. This study looked at pre-treatment biopsies to define predictors of response to treatment and mechanisms of resistance (within the cancer cells), which is critical to understanding best use of these therapies, said lead author Dr Elizabeth Swisher, professor of Obstetrics and Gynecology at the University of Washington School of Medicine, Seattle. ....
New drug class effective in treating certain types of ovarian cancers A study published today in Nature Communications shows that the drug rucaparib has been effective in treating certain types of ovarian cancers if used early in treatment, after a diagnosis, and before the cancer cells build up a resistance to chemotherapy. Rucaparib is in a relatively new class of drugs - Poly(ADP-ribose) polymerase or PARP inhibitors - which have been approved for therapy in ovarian cancers. This study provides insights into both how the cancers resist treatments, and which patients may respond favorably to the drug, said lead author Dr. Elizabeth Swisher, a UW Medicine gynecologic oncologist and a professor of obstetrics and gynecology at the University of Washington School of Medicine. She also co-directs the Breast and Ovarian Cancer Research Program at the Seattle Cancer Care Alliance. ....